StockData

Establishment Labs vs Si-Bone

ESTA and SIBN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ESTA and SIBN compare

Establishment Labs is the larger company, worth 2.0 times as much as Si-Bone ($2.1B against $1.0B).

Establishment Labs grew revenue faster over the last twelve months (38.3% versus 15.3% for Si-Bone).

Si-Bone keeps more of each dollar of sales as profit, with a net margin of −6.9% compared with −14.6% at Establishment Labs.

Si-Bone scores higher on the StockData Score (11 against 6 for Establishment Labs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricESTASIBN
Size and price
Market cap$2.1B$1.0B
Share price$69.51$23.16
Change, 1 year8.6%33.0%
Change, 5 years4.7%15.7%
Beta (5Y)0.670.31
Employees1,004376
StockData Score
Total score611 (better)
Valuation score00
Growth score34 (better)
Performance score23 (better)
Health score14 (better)
Dividend score00
Valuation
P/S7.8×4.9× (better)
P/B133×5.7× (better)
FCF yield−1.0%−0.42% (better)
Fair value–$16.33
Margin of safety–−41.8%
Growth
Revenue growth (TTM)38.3% (better)15.3%
Revenue growth, 5Y average20.0%22.3% (better)
Profitability
Gross margin70.2%79.5% (better)
Operating margin−6.6% (better)−8.3%
Net margin−14.6%−6.9% (better)
FCF margin−8.2%−2.1% (better)
Return on equity−241%−8.3% (better)
Return on invested capital−6.7% (better)−19.6%
Financial health
Debt / equity17.170.20 (better)
Interest coverage−0.6× (better)−7.1×
Current ratio3.579.15 (better)
Altman Z-score2.748.36 (better)
Piotroski F-score36 (better)
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions95.8%108%
Held by insiders9.6%3.7%
Insider net buying, 12 months−$35.5M−$14.6M (better)
Short interest, % of float14.6%10.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.